Rheumatoid Arthritis News

The FDA has approved rituximab-arrx, in combination with methotrexate, in adult patients with moderate or severely active rheumatoid arthritis who have had inadequate responses to one or more TNF agonist therapies.

CLEVELAND — It is important to implement a wellness strategy for patients who have immune-mediated inflammatory disease, according to M. Elaine Husni, MD, MPH, of the department of rheumatic and immunologic disease at the Cleveland Clinic.

CLEVELAND — Cassandra Calabrese, DO, emphasized the importance of vaccines for patients with immune-mediated inflammatory diseases at the Medical Dermatology Therapy Update II meeting.

More than half of a cohort of patients with rheumatic or musculoskeletal diseases reported experiencing some post-traumatic stress outcomes during the COVID-19 pandemic, according to data presented at the EULAR 2022 Congress.

SAN FRANCISCO — New real-world data demonstrate treatment with selexipag improved outcomes in patients with pulmonary arterial hypertension associated with connective tissue disease.

Depression is associated with a six-fold increased risk for mortality in patients with incident rheumatoid arthritis, according to data presented at the EULAR 2022 Congress.

A two-dose vaccine course is “highly effective” against COVID-19 infection and severe outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease, according to data.

DESTIN, Fla. — Switching to a different drug class with a different mechanism of action can improve response in patients with difficult-to-treat rheumatoid arthritis, according to Janet Pope, MD, of Western University, in Ontario, Canada.

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.

Glucocorticoids are still one of the most commonly used treatments for rheumatoid arthritis, with an estimated up to 50% of patients with RA in the United States using them long-term as of 2021.